Study Using PET/CT to Characterize the Effect of Reslizumab on Airway Inflammation

Study Title

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Teva Identifier

C38072-AS-40105

ClinicalTrials.gov Identifier

NCT02937168

Study Status

Terminated

Trial Condition(s)

Asthma

Interventions

Drug: Reslizumab | Drug: Fludeoxyglucose F 18 (FDG) | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 50 Years

Trial Duration

May 8, 2017 - May 24, 2017

Phase

Phase 4

Study Type

Interventional